- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene Therapeutics Announces Q2 Investor Conference Participation
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
- Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
More ▼
Key statistics
On Friday, Allogene Therapeutics Inc (ALLO:NSQ) closed at 2.32, 4.04% above its 52-week low of 2.23, set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.40 |
---|---|
High | 2.41 |
Low | 2.30 |
Bid | 2.32 |
Offer | 2.34 |
Previous close | 2.41 |
Average volume | 3.04m |
---|---|
Shares outstanding | 208.38m |
Free float | 153.43m |
P/E (TTM) | -- |
Market cap | 485.53m USD |
EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼